— Know what they know.
Not Investment Advice

AERI NASDAQ

Aerie Pharmaceuticals, Inc.
1W: +0.1% 1M: +0.3% 3M: +36.8% 1Y: +48.5% 3Y: -19.2% 5Y: -74.5%
$15.25
Last traded 2022-11-18 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Cash Flow Trends

Operating Cash Flow
-$99M -53.3% ▼
Capital Expenditures
$3M -6.2% ▼
5Y CAGR: -8.3%
Free Cash Flow
-$102M -51.1% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$114M -1599.1% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2017FY2018FY2019FY2020FY2021
— Operating Activities —
Net Income-$145M-$233M-$200M-$183M-$75M
Depreciation & Amort.$1M$2M$18M$34M$38M
Stock-Based Comp.$0$0$0$0$0
Change in Working Capital-$1M$13M-$24M$45M-$93M
Other Non-Cash Items$26M$25M$10M-$732K$1M
Operating Cash Flow-$93M-$153M-$150M-$65M-$99M
— Investing Activities —
Capital Expenditures-$16M-$31M-$10M-$3M-$3M
Acquisitions (Net)-$10M$0$0$0$0
Investment Purchases-$104M-$56M-$165M-$117M-$132M
Investment Sales$88M$108M$0$193M$117M
Other Investing-$10M$0-$8M$0$0
Investing Cash Flow-$43M$21M-$183M$73M-$18M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$136M$137M$275M-$859K$3M
Financing Cash Flow$136M$137M$275M-$859K$3M
Net Change in Cash-$376K$5M-$59M$8M-$114M
Cash End of Period$198M$203M$144M$152M$37M
Free Cash Flow-$109M-$184M-$160M-$68M-$102M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms